Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease

Does treatment with semaglutide reduce the number of total hospital admissions and duration of hospital stay in patients at high cardiovascular risk with overweight or obesity?This prespecified exploratory analysis of the SELECT randomized clinical trial observed that treatment of patients with semaglutide was associated with a lower rate of first hospital admission for any indication, total hospitalizations, and number of days hospitalized.This finding extends the benefits of treatment with semaglutide beyond cardiovascular prevention to reducing the burden of total hospital admissions.

Corresponding Author: Stephen J. Nicholls, MD, Monash Victorian Heart Institute and Monash University, 631 Blackburn Rd, Melbourne, VIC 3168, Australia (stephen.nicholls@monash.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.